Categories AlphaGraphs, Earnings, Technology

ON Semiconductor’s Q2 results decline; stock falls on disappointing revenue guidance

ON Semiconductor’s (NASDAQ: ON) bottom and top-line results for the second quarter of 2019 declined from the prior year. While earnings came in line with analysts’ predictions, revenue missed estimates. The company also reported weak guidance for Q3. Shares of ON Semiconductors were down about 7% in the pre-market trading hours.

ON Semiconductor (ON) Q2 2019 earnings results

On a non-GAAP basis, the semiconductor firm earned $0.42 per share on revenue of $1.35 billion, representing a 9% decline in EPS and a 7% decline in revenue. On a GAAP basis, EPS declined 31% year-over-year to $0.24. The market had expected ON to earn $0.42 per share on revenue of $1.38 billion.

“Business conditions continue to be soft, and we expect to see sub-seasonal demand trends in the near-term, as geopolitical factors will likely continue to weigh on demand,” said CEO Keith Jackson.

Related: Intel stock jumps as it surpasses Q2 estimates; Apple to buy its smartphone modem business for $1 billion

Based on product booking trends, backlog levels, and estimated turns levels, the company anticipates 2019 third quarter revenue to be approximately $1.36 billion to $1.41 billion. Gross margin is expected to be 35.2% to 36.2% on a GAAP basis and 36.7% to 37.7% on a non-GAAP basis.

During the second quarter, ON Semiconductor signed a definitive agreement to acquire, in a phased transaction, a 300mm fab located at East Fishkill, NY and related assets from GLOBALFOUNDRIES. The company also closed its previously announced acquisition of Quantenna Communications, a provideer of connectivity semiconductor solutions for Wi-Fi, in the second quarter.

ON stock had gained 21% since the beginning of 2019, while it had dropped 7% in the trailing 12 months.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top